Novavax (NVAX) Reports Q3 Loss of $3.21/sh

Novavax (NASDAQ: NVAX) reported Q3 EPS of ($3.21), versus $0.74 reported last year. Revenue for the quarter came in at $157 million versus the consensus estimate of $230.56 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
• Exclusive: Axe Compute CEO says prepayments cover about a third of $3bn build cost